Bone marrow-derived mesenchymal stromal cell therapy in severe covid-19: preliminary results of a phase i/ii clinical trial

HIGHLIGHTS

• who: Cu00e9line Gru00e9goire from the Berlin, Germany Tianjin University, China have published the Article: Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial, in the Journal: (JOURNAL)
• what: The authors report positive results of BM-MSCs on survival of patients with severe COVID-19, along with satisfactory safety, which will need to be confirmed in randomized placebocontrolled trials.
• how: The following clinical data were collected within 24 hours of ICU admission age body mass index (BMI) PaO2/FiO2 ratio Sepsis-related Organ . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.